Stoke Therapeutics, Inc. short interest in 2026
In 2026, Stoke Therapeutics, Inc.'s disclosed short interest ran from 19.52% of shares outstanding on 15 Jan 2026 to 17.28% on 15 Sep 2026, a change of -2.24 percentage points. The year's high was 25.20% on 15 Jul 2026 and its low 17.28% on 15 Sep 2026, averaging 20.86% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.67 days on 31 Jul 2026. Full history: Stoke Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 19.52% (15 Jan 2026)
- End of year
- 17.28% (15 Sep 2026)
- Change
- -2.24 pp
- High
- 25.20% (15 Jul 2026)
- Low
- 17.28% (15 Sep 2026)
- Average
- 20.86%
- Highest days to cover
- 27.67 (31 Jul 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 19.52% | 12.64 | results (8-K) |
| 30 Jan 2026 | 19.58% | 18.31 | |
| 13 Feb 2026 | 20.66% | 20.22 | |
| 27 Feb 2026 | 21.71% | 18.91 | |
| 13 Mar 2026 | 23.43% | 14.48 | |
| 31 Mar 2026 | 22.44% | 12.60 | 10-K filed |
| 15 Apr 2026 | 21.95% | 20.80 | |
| 30 Apr 2026 | 20.92% | 27.04 | |
| 15 May 2026 | 20.74% | 24.75 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.03% | 19.13 | |
| 15 Jun 2026 | 18.82% | 22.37 | |
| 30 Jun 2026 | 22.33% | 10.01 | |
| 15 Jul 2026 | 25.20% | 20.73 | |
| 31 Jul 2026 | 24.50% | 27.67 | |
| 14 Aug 2026 | 20.11% | 12.70 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 17.36% | 11.87 | |
| 15 Sep 2026 | 17.28% | 17.31 |
See also: Stoke Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.